INOVA Pharmaceuticals has welcomed the TGA approval of its new Contrave weight loss medication, which is a combination of naltrexone and buproprion.
Contrave is indicated, along with a reduced calorie diet and increased physical activity, for the management of weight in adults with obesity, who are overweight and have one or more weight-related co-morbidities.
Contrave was developed by Professor Michael Cowley, head of the Monash Biomedicine Discovery Institute's Department of Physiology, and works on neural pathways involved in the regulation of appetite and food cravings.
Contrave is not PBS-listed, but is available on private prescription and will cost $230-$250 per month.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Feb 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Feb 19